– UK, Scotland – eClinicalHealth Limited, a technology and consulting company dedicated to the provision of innovative clinical trial solutions is proud to announce the appointment of one of the most distinguished experts in the field of applied innovation in clinical research to chair their Industry Advisory Board.
Miguel Orri, a former Senior Director at Pfizer was previously responsible for Pfizer’s REMOTE virtual clinical trial program, Miguel will also join the Founders of eClinicalHealth as a Consulting Partner and will provide thought leadership and share his experiences with eClinicalHealth’s customers as a strategic advisor. His areas of expertise include the use of virtual clinical trial methods such as online recruitment, electronic informed consent, direct-to-patient data capture and best methods for patient engagement and retention through the study lifecycle. Miguel’s strategic and hands-on experience with these innovative concepts combined with eClinicalHealth’s capabilities will allow life science companies to successfully pilot and operationalize these new methods to enhance clinical trial efficiency.
“We’re excited to have Miguel on board to provide his expertise from the sponsor’s perspective in using new methods to increase clinical trial efficiency. These new methods and technologies are here to stay and adding Miguel to the team increases our ability to help companies adopt them more efficiently.” says Douglas Bain, eClinicalHealth’s CEO and Co-founder.
About the Company
Headquartered in Scotland, eClinicalHealth Limited, developers of the revolutionary Clinpal patient engagement platform, was founded in early 2012 to provide innovative clinical trial solutions. The Company is committed to leading open and collaborative innovation discussions about virtual clinical trial processes and technology with pharmaceutical companies, CROs and other service and technology providers.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.